Colorectal Cancer: A Complete Guide for International Patients in Shanghai

Introduction

Colorectal cancer (CRC) — cancer of the colon or rectum — is the third most commonly diagnosed cancer and the second leading cause of cancer death worldwide. In China, it is the second most common cancer by incidence and its prevalence is rising rapidly, driven by dietary westernization, sedentary lifestyles, and an aging population.

The critical message about colorectal cancer is one of hope: when detected early, it is highly treatable and often curable. The five-year survival rate for localized (Stage I) colorectal cancer exceeds 90%. Yet when diagnosed at an advanced stage, survival rates drop dramatically. This makes screening — detecting cancer or pre-cancerous polyps before symptoms develop — the single most important tool in fighting this disease.

For international patients and expatriates in Shanghai, this guide provides a comprehensive overview of colorectal cancer: risk factors, symptoms, screening, diagnosis, treatment, and how to access world-class colorectal surgery and oncology care in Shanghai.

Understanding Colorectal Cancer

The colon (large intestine) and rectum form the final section of the digestive tract. Colorectal cancer almost always begins as a small, benign growth called a polyp on the inner lining of the colon or rectum. Over time — typically 10–15 years — certain types of polyps (particularly adenomatous polyps) can transform into cancer. This slow progression is precisely what makes screening so powerful: removing polyps before they become cancerous prevents cancer from developing at all.

The vast majority of colorectal cancers are adenocarcinomas (arising from the glandular cells lining the colon). Less common types include mucinous adenocarcinoma, signet ring cell carcinoma, neuroendocrine tumors, and lymphomas of the colon.

Stages of Colorectal Cancer

Colorectal cancer is staged using the TNM system (Tumor, Node, Metastasis) and grouped into four stages:

• Stage I: Cancer is confined to the inner layers of the colon or rectal wall. 5-year survival rate: >90%.
• Stage II: Cancer has grown through the wall of the colon or rectum but has not spread to nearby lymph nodes. 5-year survival rate: 70–85%.
• Stage III: Cancer has spread to nearby lymph nodes but not to distant organs. 5-year survival rate: 40–70%.
• Stage IV (Metastatic): Cancer has spread to distant organs, most commonly the liver and lungs. 5-year survival rate: 10–15%, though improving with modern therapies.

Risk Factors

Non-Modifiable Risk Factors

• Age: Risk increases significantly after age 45–50. The majority of cases occur in people over 50.
• Personal history: Prior colorectal cancer, adenomatous polyps, or inflammatory bowel disease (Crohn’s disease or ulcerative colitis)
• Family history: First-degree relative with colorectal cancer or advanced polyps significantly increases risk
• Hereditary syndromes: Lynch syndrome (HNPCC) and familial adenomatous polyposis (FAP) carry very high lifetime risk and require specialized surveillance
• Type 2 diabetes

Modifiable Risk Factors

• Diet: High consumption of red meat (especially processed meat such as bacon, sausage, and deli meats) is strongly associated with increased CRC risk. Low fiber intake is also a risk factor.
• Obesity: Particularly abdominal obesity
• Physical inactivity
• Alcohol consumption: Even moderate alcohol intake increases risk
• Smoking
• Shanghai context: Increasing consumption of processed foods, red meat, and alcohol alongside declining physical activity mirrors the dietary patterns driving rising CRC rates in urban China

Symptoms

Early colorectal cancer often causes no symptoms — another reason why screening is so important. When symptoms do occur, they may include:

• A change in bowel habits lasting more than a few weeks (diarrhea, constipation, or narrowing of stool)
• Rectal bleeding or blood in the stool (bright red or very dark)
• Persistent abdominal discomfort (cramping, gas, or pain)
• A feeling that the bowel does not empty completely
• Unexplained weight loss
• Fatigue and weakness (often due to iron-deficiency anemia from occult bleeding)
• Nausea or vomiting (in advanced cases with bowel obstruction)

Do not ignore rectal bleeding or persistent changes in bowel habits. While these symptoms have many benign causes, they warrant prompt medical evaluation to exclude colorectal cancer.

Screening: The Most Powerful Tool

Colorectal cancer screening saves lives by detecting cancer at an early, curable stage — or by removing pre-cancerous polyps before cancer develops. International guidelines recommend that average-risk individuals begin screening at age 45–50. Those with higher risk (family history, hereditary syndromes, IBD) should begin earlier and screen more frequently.

Screening Options

• Colonoscopy: The gold standard. A flexible camera is used to examine the entire colon and rectum. Polyps can be removed during the same procedure. Recommended every 10 years for average-risk individuals with normal findings. Available at all major Shanghai hospitals.
• Fecal Immunochemical Test (FIT): A stool test that detects hidden (occult) blood. Non-invasive, performed at home. Recommended annually. A positive result requires follow-up colonoscopy.
• Fecal DNA test (Cologuard): Detects DNA mutations and blood in stool. More sensitive than FIT but less widely available in China.
• CT Colonography (Virtual Colonoscopy): A CT scan of the colon. Less invasive than colonoscopy but requires bowel preparation and cannot remove polyps. Available at major Shanghai hospitals.
• Flexible Sigmoidoscopy: Examines only the lower portion of the colon. Less comprehensive than full colonoscopy.

For international patients in Shanghai, colonoscopy is the most practical and comprehensive screening option. CMCS can coordinate screening colonoscopy at leading hospitals with full interpretation support.

Diagnosis

When colorectal cancer is suspected — based on symptoms, a positive screening test, or clinical findings — the diagnostic workup includes:

• Colonoscopy with biopsy: Definitive diagnosis requires tissue sampling. A biopsy taken during colonoscopy is examined by a pathologist to confirm cancer and determine its type and grade.
• CT scan of chest, abdomen, and pelvis: To assess the extent of local disease and detect distant metastases (liver, lungs, peritoneum).
• MRI of the pelvis: Essential for rectal cancer to assess local tumor extent, involvement of the mesorectal fascia, and lymph node status — critical for surgical planning.
• PET-CT scan: May be used to detect occult metastases in selected cases. Available at major Shanghai hospitals.
• Blood tests: CEA (carcinoembryonic antigen) is a tumor marker used for monitoring treatment response and detecting recurrence, not for primary diagnosis. Full blood count, liver function, and kidney function are also assessed.
• Molecular and genetic testing: Tumor tissue is tested for microsatellite instability (MSI), mismatch repair (MMR) status, KRAS, NRAS, BRAF, and HER2 mutations — critical for determining eligibility for targeted therapy and immunotherapy, and for identifying Lynch syndrome.

Treatment

Treatment of colorectal cancer is multidisciplinary, involving colorectal surgeons, medical oncologists, radiation oncologists, radiologists, and pathologists. Treatment decisions are made based on tumor stage, location (colon vs. rectum), molecular profile, and the patient’s overall health.

Surgery

Surgery is the primary treatment for localized colorectal cancer and the only potentially curative option for most patients.

• Colectomy: Removal of the affected segment of the colon along with surrounding lymph nodes (oncological resection). Can be performed as open surgery or minimally invasive laparoscopic/robotic surgery. Minimally invasive approaches offer faster recovery and are the standard of care at leading Shanghai hospitals.
• Rectal surgery: More complex than colon surgery due to the anatomy of the pelvis. Procedures include low anterior resection (LAR) and abdominoperineal resection (APR). Total mesorectal excision (TME) is the surgical standard for rectal cancer.
• Stoma: Some patients require a temporary or permanent colostomy or ileostomy (an opening in the abdominal wall for waste elimination). Modern surgical techniques minimize the need for permanent stomas.
• Liver metastasectomy: In selected patients with liver-only metastases, surgical removal of liver metastases can be curative. Shanghai’s leading hepatobiliary surgeons have extensive experience with this procedure.

Chemotherapy

• Adjuvant chemotherapy: Given after surgery to reduce the risk of recurrence in Stage III and selected Stage II patients. Standard regimens include FOLFOX (oxaliplatin + leucovorin + 5-fluorouracil) or CAPOX (capecitabine + oxaliplatin).
• Neoadjuvant chemotherapy: Given before surgery to shrink the tumor and improve resectability, particularly in rectal cancer and metastatic disease.
• Palliative chemotherapy: For Stage IV disease, chemotherapy extends survival and improves quality of life. Regimens include FOLFOX, FOLFIRI, and FOLFOXIRI.

Targeted Therapy

Molecular testing of the tumor guides the use of targeted agents:

• Anti-VEGF agents (bevacizumab): Added to chemotherapy for metastatic CRC regardless of molecular profile
• Anti-EGFR agents (cetuximab, panitumumab): Effective in RAS wild-type (KRAS/NRAS unmutated) metastatic CRC
• BRAF inhibitors (encorafenib + cetuximab): For BRAF V600E-mutated metastatic CRC
• HER2-targeted therapy: For HER2-amplified metastatic CRC

Immunotherapy

Immune checkpoint inhibitors (pembrolizumab, nivolumab) are highly effective in the subset of colorectal cancers with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors — approximately 5% of metastatic CRC. MSI-H status is now routinely tested at leading Shanghai hospitals. Pembrolizumab is approved in China for MSI-H metastatic CRC.

Radiation Therapy

Radiation is used primarily in rectal cancer (not colon cancer) as part of multimodal treatment:

• Neoadjuvant chemoradiation: Standard of care for locally advanced rectal cancer prior to surgery, to shrink the tumor and reduce local recurrence risk
• Short-course radiotherapy: An alternative neoadjuvant approach increasingly used in selected rectal cancer patients
• Palliative radiation: To control bleeding, pain, or obstruction in advanced disease

Watch and Wait (Non-Operative Management)

In selected rectal cancer patients who achieve a complete clinical response to neoadjuvant chemoradiation, a non-operative “watch and wait” approach may be considered, avoiding surgery and preserving bowel function. This approach requires close surveillance and is offered at specialized centers.

Survivorship & Follow-Up

After curative treatment, regular surveillance is essential to detect recurrence early:

• CEA blood test every 3–6 months for the first 3 years, then annually
• CT scan of chest, abdomen, and pelvis every 6–12 months for 3–5 years
• Colonoscopy at 1 year post-surgery, then every 3–5 years
• Management of treatment side effects: peripheral neuropathy (from oxaliplatin), bowel dysfunction, fatigue, and psychological impact
• Lifestyle optimization: diet, exercise, weight management, and smoking cessation to reduce recurrence risk

Colorectal Cancer Care in Shanghai

Shanghai is home to some of China’s leading colorectal cancer centers. Key considerations for international patients:

• Surgical expertise: Zhongshan Hospital, Ruijin Hospital, and Renji Hospital have nationally recognized colorectal surgery departments with high-volume experience in laparoscopic and robotic surgery.
• Multidisciplinary tumor boards (MDT): Leading Shanghai hospitals conduct regular MDT meetings where complex cases are reviewed by surgeons, oncologists, radiologists, and pathologists — ensuring treatment decisions reflect the latest evidence.
• Molecular testing: Comprehensive tumor molecular profiling (MSI, RAS, BRAF, HER2) is available at major Shanghai hospitals and is essential for treatment planning.
• Targeted therapies and immunotherapy: Most approved agents are available in China, though access and reimbursement pathways differ from Western markets. CMCS can assist with navigating access to specific treatments.
• Language and navigation: Coordinating care across surgery, oncology, and radiation departments in a Chinese hospital system is complex. CMCS provides end-to-end coordination and interpretation.

How China Medical Concierge Shanghai (CMCS) Can Help

A colorectal cancer diagnosis is life-changing. Navigating treatment in a foreign country adds significant stress. CMCS provides comprehensive support at every stage of the journey:

• Specialist matching: Connecting you with leading colorectal surgeons, medical oncologists, and radiation oncologists at Shanghai’s top hospitals
• MDT coordination: Facilitating access to multidisciplinary tumor board review for complex cases
• Appointment booking: Priority scheduling across multiple specialties
• Medical interpretation: Professional interpreters for all consultations, procedures, and treatment discussions
• Second opinion coordination: Arranging second opinions from leading specialists, including remote consultations with international centers
• Insurance coordination: Liaising with your international health insurer for treatment approvals and claims
• Screening coordination: Arranging colonoscopy screening for patients who are due or overdue for screening
• Survivorship support: Coordinating ongoing surveillance, follow-up appointments, and supportive care

📩 Contact CMCS today for a free initial consultation.

Frequently Asked Questions

At what age should I start colorectal cancer screening?
International guidelines recommend starting screening at age 45–50 for average-risk individuals. If you have a first-degree relative with colorectal cancer or advanced polyps, screening should begin 10 years before the age at which your relative was diagnosed, or at age 40 — whichever comes first. CMCS can help you determine the right screening schedule for your individual risk profile.

Is colonoscopy safe and available in Shanghai?
Yes. Colonoscopy is widely available at Shanghai’s major hospitals and is performed to a high standard. Sedation is routinely offered. CMCS can coordinate your colonoscopy with full interpretation support to ensure a comfortable and well-managed experience.

What is the difference between colon cancer and rectal cancer?
Both arise from the same tissue and share many risk factors, but they differ in location, surgical approach, and the role of radiation therapy. Rectal cancer treatment is more complex and typically involves a combination of surgery, chemotherapy, and radiation. Treatment planning requires MRI of the pelvis and specialist colorectal surgical expertise.

Can colorectal cancer be cured?
Yes — when detected at an early stage, colorectal cancer is highly curable. Stage I disease has a greater than 90% five-year survival rate. Even Stage III disease is curable in many patients with surgery and adjuvant chemotherapy. This is why early detection through screening is so critical.

What is MSI and why does it matter?
Microsatellite instability (MSI) is a molecular characteristic of the tumor. MSI-high (MSI-H) tumors respond exceptionally well to immunotherapy (checkpoint inhibitors such as pembrolizumab) and have a better prognosis in early-stage disease. MSI testing is now standard practice and should be performed on all colorectal cancer tumors.

Is colorectal cancer treatment covered by international health insurance?
Yes. Cancer diagnosis and treatment — including surgery, chemotherapy, targeted therapy, and radiation — are covered by most international health insurance plans. Coverage for specific newer agents may vary. CMCS can verify your coverage and manage the prior authorization and claims process.